Neurofibromatosis 1
An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).
Drugs by status
Approved for this indication (1)
Phase 4 trials (3)
Phase 3 trials (3)
Phase 2 trials (34)
- diclofenac
- azacitidine
- abemaciclib
- aminolevulinic acid
- apg-115
- acetylcysteine
- binimetinib
- busulfan
- lenalidomide
- doxorubicin
- naltrexone
- levetiracetam
- pirfenidone
- ifosfamide
- zarnestra
- celecoxib
- sirolimus
- temozolomide
- bevacizumab
- everolimus
- vinblastine
- fludarabine
- cediranib
- rituximab
- lovastatin
- etoposide
- sargramostim
- cytarabine
- melphalan
- interferon alpha-2b
- +4 more
Phase 1 trials (11)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (57)
- Takeda
- AstraZeneca
- Genentech
- Pfizer
- Array BioPharma
- Bayer
- Betta Pharmaceuticals Co.,Ltd.
- GlaxoSmithKline
- PTC Therapeutics
- Simcere Pharmaceutical Co., Ltd
- Fundação Educacional Serra dos Órgãos
- National Institutes of Health (NIH)
- United States Army
- Region Skane
- Beijing Tiantan Hospital
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- University of London
- Cornell University
- Harvard University
- Indiana University
- Johns Hopkins University
- Lund University
- Michigan State University
- New York University
- Northwestern University
- Pediatric Brain Tumor Consortium
- Sarcoma Alliance for Research through Collaboration
- University of Hamburg
- +27 more
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (1)